Secukinumab Improves Patient-Reported Outcomes in Subjects with Active Psoriatic Arthritis: Results from a Randomised Phase III Trial (FUTURE 1) - Sorbonne Université Access content directly
Journal Articles Annals of the Rheumatic Diseases Year : 2017

Secukinumab Improves Patient-Reported Outcomes in Subjects with Active Psoriatic Arthritis: Results from a Randomised Phase III Trial (FUTURE 1)

Abstract

OBJECTIVE: To evaluate the effect of secukinumab on patient-reported outcomes (PROs) in subjects with active psoriatic arthritis (PsA) in the FUTURE 1 study. METHODS: Subjects were randomised 1:1:1 to receive intravenous (i.v.) secukinumab 10\hspace0.25emmg/kg at weeks 0, 2 and 4 followed by subcutaneous secukinumab 150 or 75\hspace0.25emmg every 4\hspace0.25emweeks or matching placebo until week 24. RESULTS: At week 24, subjects receiving secukinumab i.v.\textrightarrow 150\hspace0.25emmg or i.v.\textrightarrow 75\hspace0.25emmg reported greater least squares mean changes from baseline than those receiving placebo in patient global assessment of disease activity (-20.6 and -20.0 vs -7.4, respectively), patient assessment of pain (-20.8 and -20.4 vs -6.7), psoriatic arthritis quality of life (-3.5 and -3.2 vs -0.4), Dermatology Life Quality Index (-8.8 and -7.9 vs 0.7); p<0.0001 vs placebo for both secukinumab groups for above PROs and Functional Assessment of Chronic Illness Therapy-Fatigue (6.74 (p<0.05 vs placebo) and 6.03 vs 4.00); all of which well exceeded minimum clinically important differences. CONCLUSIONS: In subjects with PsA, secukinumab treatment resulted in clinically meaningful improvements in global disease activity, pain, generic and disease-specific measures of health-related quality of life and fatigue. TRIAL REGISTRATION NUMBER: NCT01392326; Results.
No file

Dates and versions

hal-03895160 , version 1 (12-12-2022)

Identifiers

Cite

Vibeke Strand, Philip Mease, Laure Gossec, Ori Elkayam, Filip van Den Bosch, et al.. Secukinumab Improves Patient-Reported Outcomes in Subjects with Active Psoriatic Arthritis: Results from a Randomised Phase III Trial (FUTURE 1). Annals of the Rheumatic Diseases, 2017, 76 (1), pp.203--207. ⟨10.1136/annrheumdis-2015-209055⟩. ⟨hal-03895160⟩
9 View
0 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More